摘要
柯萨奇B组病毒(CVB)是引起人类病毒性心肌炎(VM)的最常见病原体,CVB感染心肌细胞主要是通过与柯萨奇病毒和腺病毒受体(CAR)及衰变加速因子(DAF/CD55)这2种受体蛋白的相互作用完成。近年来,病毒受体陷阱(virus receptor trap)已被用于治疗实验性小鼠CVB3心肌炎,并已显示出良好的抗病毒效果。所谓"病毒受体陷阱疗法"是指利用人工合成的可溶性病毒受体来结合病毒,从而阻断病毒与靶细胞膜上的受体结合及随后的病毒内吞。病毒受体陷阱疗法加深了对VM发病机制的理解,拓展了VM的治疗策略,有望成为急性VM一个新的有效治疗手段。
Coxsackievirus B （CVB） is the most common pathogen that causes human viral myocarditis. CVB predominantly interacts with two receptors, the coxsackievirus and adenovirus receptor （CAR） and the decay-accelerating factor （DAF/CD55）, for the attachment at myocardial cell surface and the subsequent internalization. In recent years, virus receptor trap has been used to neutralize CVB3 in experimental murine viral myocarditis and has demonstrated good antiviral effects. The so-called ＂virus receptor trap therapy＂ refers to the use of synthetic soluble virus receptor to bind to virus and thereby blocks the binding of virus to the target cell membrane receptors and the subsequent internalization. The virus receptor trap therapy deepens the understanding of the pathogenesis of viral myocarditis, expands the treatment strategy and may be used as a potential candidate for a novel therapeutic agent for the treatment of acute viral myocarditis.
出处
《临床儿科杂志》
CAS
CSCD
北大核心
2007年第10期801-804,866,共5页
Journal of Clinical Pediatrics
